Curacle is a Korean biopharmaceutical company leading the research and development of new drugs in the field of intractable vascular diseases.
Curacle's research focuses on the development of endothelial dysfunction blockers utilizing the SOLVADYS® platform.
We are conducting research and development in various therapeutic areas with high potential for business and clinical differentiation, including CU06, a retinal vascular disease treatment, and aiming to achieve the goal of being the first Korean company to launch a blockbuster drug through development of a First-in-Class drug.

CURACLE

Org chart

Teams

Offices